Metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH), are biologically interconnected and frequently comorbid, creating both opportunities and challenges for therapeutic development. GLP-1 receptor agonists and related incretin-based therapies have reshaped the treatment landscape, while expanding indications and therapeutic modalities raise new questions about disease-relevant models and drug disposition.
This webinar will provide an overview of metabolic disease biology and the evolving GLP-1 therapeutic landscape, followed by examples illustrating how high-quality human biospecimens, primary cells, subcellular fractions, advanced hepatic models and in vitro ADME studies can support drug discovery and development.
The second portion will present a case study comparing the clearance and biotransformation of semaglutide and tirzepatide in sandwich-cultured human hepatocytes, liver and kidney S9 fractions, and human liver lysosomes. Clearance kinetics, peptide cleavage profiles, and proteomics will demonstrate why similar loss of parent compound does not necessarily reflect the same underlying metabolic pathways, and why fit-for-purpose test-system selection is critical when evaluating therapeutic peptide metabolism.
Featuring Insights from
Brian Ogilvie
PhD
Dr. Brian W. Ogilvie joined XenoTech in 1997 and was instrumental in developing its reputation as a company dedicated to designing and implementing in vitro ADME programs that achieve clients' objectives, whether that is proof of concept, lead optimization, in-licensing or out-licensing assets, or taking drug candidates through an IND submission and clinical development. When XenoTech joined BioIVT in 2022, Brian assumed his current role as Vice President of Scientific Consulting, advising clients on preclinical strategies that will achieve their R&D goals. Brian earned his Ph.D. in toxicology from the University of Kansas Medical Center.
Joanna E. Barbara
PhD
Dr. Joanna E. Barbara is the General Manager of ADME Services at BioIVT. Joanna obtained her Ph.D. in Analytical Chemistry from the University of Florida. She has extensive experience in qualitative and quantitative LC-MS, specializing in high-resolution mass spectrometry, in conjunction with drug metabolism and drug-drug interaction expertise. Since 2007, Joanna has worked at the BioIVT Kansas City site (formerly XenoTech, LLC), serving in various mass spectrometry and scientific leadership roles. Her research integrates analytical chemistry and enzymology to understand and predict human metabolic clearance, drug disposition, and drug safety profiles. Recent research has focused on the development of translational in vitro approaches for studying the metabolism of emerging therapeutic modalities.
Sponsored by
.avif)
